Liposomal nanocarriers containing siRNA as small molecule-based drugs to overcome cancer drug resistance.
MDR
cancer
codelivery
liposomal nanocarriers
siRNA drugs
Journal
Nanomedicine (London, England)
ISSN: 1748-6963
Titre abrégé: Nanomedicine (Lond)
Pays: England
ID NLM: 101278111
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
medline:
29
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
ppublish
Résumé
This review discusses the application of nanoliposomes containing siRNA/drug to overcome multidrug resistance for all types of cancer treatments. As drug resistance-associated factors are overexpressed in many cancer cell types, pumping chemotherapy drugs out of the cytoplasm leads to an inadequate therapeutic response. The siRNA/drug-loaded nanoliposomes are a promising approach to treating multidrug-resistant cancer, as they can effectively transmit a small-molecule drug into the target cytoplasm, ensuring that the drug binds efficiently. Moreover, nanoliposome-based therapeutics with advances in nanotechnology can effectively deliver siRNA to cancer cells. Overall, nanoliposomes have the potential to effectively deliver siRNA and small-molecule drugs in a targeted manner and are thus a promising tool for the treatment of cancer and other diseases.
Identifiants
pubmed: 37965906
doi: 10.2217/nnm-2023-0176
doi:
Substances chimiques
RNA, Small Interfering
0
Liposomes
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM